Comparing the current results to its competitors, Merck And Co Inc reported Revenue increase in the 2 quarter 2026 by 5.07 % year on year. The sales growth was above Merck And Co Inc 's competitors' average revenue growth of 4.77 %, achieved in the same quarter.
Merck And Co Inc 's Comment on Competition and Industry Peers
The Company operates in highly competitive and regulated pharmaceutical markets. Its competitors include global research-based pharmaceutical companies, smaller research firms with limited therapeutic focus, generic drug manufacturers, and animal health care companies. The Company faces challenges from generic and biosimilar competition as its products mature, technological advances by competitors, industry consolidation, patents granted to competitors, competitive combination products, new competitor products, availability of generic or biosimilar versions of competitors' branded products, and new clinical trial or post-marketing surveillance data. Patent rights are increasingly contested by competitors, with uncertain outcomes that may impact commercialization, sales, royalties, or intangible asset impairments. The Company is jointly developing and commercializing Keytruda with AstraZeneca.
With revenue growth of 5.07 % within Overall company, Merck and Co Inc achieved improvement in market share, within Overall company to approximately 15.33 %. << More on MRK Market Share.
*Market share is calculated based on total revenue.
June 13, 2025
AbstractThe recent approvals of KEYTRUDA (pembrolizumab) signify a substantial advancement in the treatment landscape for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). Merck s collaborations further bolster its commitment to innovating therapeutic interventions across multiple oncological pathways. This article outlines key developments in Merck s oncology portfolio and assesses their implications for the company s strategic landscape and market position. Merck and Co., Inc., known as MSD outside the United States and Canada, has made significant strides in oncology with its groundbreaking product KEYTRUDA, an anti-PD-1 therapy that has been pivotal in reimagining tre...
March 27, 2025
Innovative Advances in Immuno-Oncology: Subcutaneous Pembrolizumab Shows Promising Results in Latest Phase 3 Trial In a groundbreaking step for cancer treatment delivery methods, Merck and Co. also known as MSD outside the United States and Canada, has revealed pivotal findings from their Phase 3 clinical trial, coded as 3475A-D77. The trial assessed the pharmacokinetics and efficacy of a subcutaneous formulation of pembrolizumab, known for its brand name KEYTRUDA, enhanced with berahyaluronidase alfa, against the traditional intravenous (IV) form. As reported, this new subcutaneous method demonstrates noninferior pharmacokinetics compared to its IV counterpart, providing a promising alternative for patients...
November 19, 2024
In the rapidly evolving realm of oncology therapies, the recent announcement by Merck and Co. Inc. (referred to as Merck) regarding the positive topline results from its pivotal Phase 3 trial (MK-3475A-D77) has elicited significant attention. This trial assessed the noninferiority of subcutaneous pembrolizumab, an anti-PD-1 therapeutic agent, under the brand name KEYTRUDA, when administered alongside berahyaluronidase alfa, a hyaluronidase variant. This article will synthesize pertinent facts from the trial s outcomes and the current financial landscape for Merck, ultimately assessing their collective impact on the company. Key Findings from the Phase 3 Trial1. Positive Topline Results : The Phase 3 MK-347...
October 8, 2024
: This article presents an examination of recent pivotal clinical trials highlighting Merck s continued advancements in the field of oncology and ophthalmology. The focus is on KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, and its impact on head and neck squamous cell carcinoma and melanoma, as well as the initiation of a new trial for Restoret (MK-3000) in diabetic macular edema. 1. Merck, known as MSD outside the United States and Canada, has been at the forefront of pharmaceutical innovation, particularly in developing treatments for challenging cancer types and ocular disorders. This article evaluates multiple recent reports involving Merck’s therapeutic agents, showcasing advancements and poten...
August 29, 2024
Merck Discontinues KEYTRUDA Phase 3 Trial Amidst New Developments In the realm of pharmaceutical endeavors, the esteemed enterprise Merck, known as MSD beyond the borders of the United States and Canada, has furnished the public with significant updates regarding their Phase 3 trials, specifically KEYNOTE-867 and KEYNOTE-630. The disclosure, made from their headquarters in Rahway, New Jersey, reverberates through the corridors of medicinal advancement with gravity and import.The spotlight of this disclosure is cast upon the forthcoming discontinuation of the KEYNOTE-867 trial, a notable phase 3 study assessing the efficacy of KEYTRUDA (pembrolizumab) in concert with stereotactic body radiotherapy (SBRT). Thi...
August 9, 2024
The pharmaceutical landscape is a dynamic and competitive arena where strategic acquisitions and collaborations can substantially shape a company’s portfolio. Merck and Co., Inc. (known as MSD outside the United States and Canada) has made significant strides in diversifying its therapeutic offerings through the acquisition of novel investigational therapies. This article discusses recent initiatives by Merck to bolster its treatment capabilities in B-cell associated diseases and oncology, while also addressing challenges faced by its partner in bringing innovative therapies to market. Merck s Acquisition of CN201 In a noteworthy move to expand its drug development pipeline for B-cell associated diseas...
July 1, 2024
RAHWAY, N.J. - Merck, a leading global pharmaceutical company, and Orion Corporation, a Finnish pharmaceutical company, have announced the mutual exercise of an option to convert their ongoing co-development and co-commercialization agreement into an exclusive global license for Merck. This includes the rights to opevesostat (MK-5684/ODM-208), an investigative CYP11A1 inhibitor, along with other candidates targeting CYP11A1. This significant collaboration signifies a major stride in the field of oncology, particularly for the treatment of metastatic castration-resistant prostate cancer.The decision to exercise the option was driven by the notable progress made in the development of opevesostat. As an investi...
June 25, 2024
Rahway, N.J. - In a landmark development, Merck Animal Health, operating as MSD Animal Health outside the U.S. and Canada, a division of Merck and Co., Inc. (NYSE: MRK), proudly announces the U.S. Department of Agriculture s (USDA) approval of NOBIVAC NXT Canine Flu H3N2. This vaccine is celebrated as the first and only RNA-particle technology vaccine for canine influenza, marking a significant leap forward in veterinary medicine. Anticipated to be available in veterinary clinics and hospitals nationwide by late summer, this cutting-edge solution aims to provide unparalleled protection for dogs against the persistent threat of canine influenza.NOBIVAC NXT Canine Flu H3N2 introduces an innovative approach to ...
May 29, 2024
Breaking New Ground: Merck s Pioneering Efforts with KEYTRUDA and Financial Triumphs Highlighted Merck Takes a Leap with FDA s Priority Review for KEYTRUDA Plus Chemotherapy for Malignant Pleural Mesothelioma Merck and Co., Inc., known as MSD outside the United States and Canada, has once again set a benchmark in the pharmaceutical industry. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its new supplemental Biologics License Application (sBLA). This application seeks approval for the use of KEYTRUDA (pembrolizumab), Merck s pioneering anti-PD-1 therapy, in combination with chemotherapy as a first-line treatment for patients with unresectable advanced o...
March 28, 2024
Boosting its cancer-fighting arsenal, pharmaceutical powerhouse Merck and Co., also known internationally as MSD, secured the European Commission s approval for KEYTRUDA (pembrolizumab) plus platinum-containing chemotherapy treatment for patients with resectable non-small cell lung cancer (NSCLC) who are at high risk of recurrence. This significant development comes on the heels of Merck finalizing its acquisition of Harpoon Therapeutics, Inc., demonstrating the company s relentless commitment to sharpening its oncology capabilities.The New Jersey-based multinational corporation announced disjunctionally these successes, which promise to widen its footprint within the global oncology sector. Merck s KEYTRUDA...
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
2seventy Bio Inc operates on a business model centered around the development and commercialization of innovative genetic therapies. They strive to harness the power of biotechnology to address complex diseases and improve patient outcomes. By advancing their proprietary gene delivery technologies and collaborating with industry partners, they aim to create scalable treatments that revolutionize the field of genetic medicine.
Acurx Pharmaceuticals Inc. operates by developing and commercializing novel antibiotics to address the growing problem of bacterial antibiotic resistance. The company focuses on targeting serious and life-threatening infections caused by multi-drug-resistant bacterial strains. Acurx Pharmaceuticals aims to bring innovative solutions to market through research and development, strategic partnerships, and a strong emphasis on improving patient outcomes.
Tempest Therapeutics Inc is a biotechnology company focused on developing small molecule therapeutics to treat cancer and other diseases. Their business model revolves around identifying novel targets within the immune system and designing drugs that modulate these targets to enhance the body's immune response against cancer cells. Through strategic collaborations and partnerships, they aim to accelerate the development and commercialization of their product candidates.
Sources:
Merck and Co Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Merck and Co Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
